Bicycle Therapeutics PLC expected to post a loss of $1.06 a share - Earnings Preview

Bicycle Therapeutics

27/02/2023 16:32

* Bicycle Therapeutics PLC  BCYC.OQ   BCYC.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 1
(estimated). 
    * The Cambridge Cambridgeshire-based  company is expected to
report  a 3.1% increase in revenue to $3.887 million from $3.77
million a year ago, according to the mean estimate from 13
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Bicycle
Therapeutics PLC
is for a loss of $1.06 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is $52.5​, above​ its last closing price
of $22.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.86       -0.89      -0.96     Missed  -8
 Jun. 30 2022  -0.89       -0.85      -0.90     Missed  -6.1
 Mar. 31 2022  -0.70       -0.68      -0.93     Missed  -36.4​
 Dec. 31 2021  -0.67       -0.61      -0.63     Missed  -3.1
 ​​Sep.        -0.63       -0.61      -0.59     Beat    3.5
 30 2021                                                
 Jun. 30 2021  -0.68       -0.73      -0.74     Missed  -1.9​
 Mar. 31 2021  -0.73       -0.71      -0.73     Missed  -3.3
 Dec. 31 2020  -0.54       -0.47      -0.83     Missed  -75.7
 This summary was machine generated February 27 at 16:32 GMT. 
All figures in US dollars  unless otherwise stated